Below are the latest Acta Pharmacologica Sinica articles published online ahead of print publication.
Currently no content available!
- Home /
- Home
Forthcoming Special Issue on Circulating Biomarkers for Cardiovascular Diseases
A special issue on “Circulating Biomarkers for Cardiovascular Diseases” will be published by Acta Pharmacologica Sinica in May 2018. Authors are warmly invited to submit original articles or reviews related to the topics.
Therapeutic gene editing: delivery and regulatory perspectives
Gene-editing technology is an emerging therapeutic modality for manipulating the eukaryotic genome by using target-sequence- speci c engineered nucleases. Because of the exceptional advantages that gene-editing technology offers in facilitating the accurate correction of sequences in a genome, gene editing-based therapy is being aggressively developed as a next-generation therapeutic approach to treat a wide range of diseases.
Defining the minimum substrate and charge recognition model of gamma-secretase
γ-Secretase is an intramembrane aspartyl protease that cleaves the C99 fragment of amyloid precursor protein to generate extracellular Aβ peptides. These peptides can oligomerize and aggregate to form amyloid plaques, processes that are widely believed to be causal for Alzheimer’s disease. In spite of this critical function, it remains unknown how γ-secretase recognizes C99 and its other substrates, including Notch.
Insights into molecular therapy of glioma: current challenges and next generation blueprint
Glioma accounts for the majority of human brain tumors. With prevailing treatment regimens, the patients have poor survival rates. In spite of current development in mainstream glioma therapy, a cure for glioma appears to be out of reach. The infiltrative nature of glioma and acquired resistance substancially restrict the therapeutic options. Better elucidation of the complicated pathobiology of glioma and proteogenomic characterization might eventually open novel avenues for the design of more sophisticated and effective combination regimens.
Progress and prospects in stem cell therapy
In the past few years, progress being made in stem cell studies has incontestably led to the hope of developing cell replacement based therapy for diseases deficient in effective treatment by conventional ways. The induced pluripotent stem cells (iPSCs) are of great interest of cell therapy research because of their unrestricted self-renewal and differentiation potentials.
Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier
To achieve synergistic therapeutic ef cacy and prevent cancer relapse, chemotherapy and immunotherapy have been combined asa new modality for tumor treatment. In this work, we designed a redox-responsive immunostimulatory polymeric prodrug carrier, PSSN10, for programmable co-delivery of an immune checkpoint inhibitor NLG919 (NLG) and a chemotherapeutic doxorubicin (DOX).
Androgen receptor: structure, role in prostate cancer and drug discovery
Androgens and androgen receptors (AR) play a pivotal role in expression of the male phenotype. Several diseases, such as androgen insensitivity syndrome (AIS) and prostate cancer, are associated with alterations in AR functions. Indeed, androgen blockade by drugs that prevent the production of androgens and/or block the action of the AR inhibits prostate cancer growth. However, resistance to these drugs often occurs after 2–3 years as the patients develop castration-resistant prostate cancer (CRPC). In CRPC, a functional AR remains a key regulator.
ISSN: 1671-4083
EISSN: 1745-7254
2016 Impact Factor 3.223*
55/166 Chemistry, Multidisciplinary
74/256 Pharmacology & Pharmacy
Jian Ding
*2016 Journal Citation Reports® Science Edition
Society Resources
Publishing Information
Acta Pharmacologica Sinica is published by SPRINGER NATURE
Membership
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.
